Yunfeng Liu, [email protected] These authors have contributed equally to this work and share first authorship These authors have contributed equally to this work This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology ORCID: Yi Zhang, orcid.org/0000-0003-0305-3127 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Frequently Asked Questions About Digestive Bitters and GLP-1 What is GLP-1 and why does it matter for metabolism
The Microdose Protocol works especially well for patients who want to test whether GLP-1 therapy suits their metabolism and lifestyle before committing to higher monthly expenses
"FDA's June 2026 Compounding Proposal" refers to the FDA's publicly announced proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list, with a public comment period open through June 2026 - this is a factual regulatory event documented in the Federal Register and at FDA.gov, not a determination specific to FeelGood
Just two years later, in 2024, prescriptions cost the state $650 million, and were projected to double this year
But individual consumers need to be their own first line of defense, armed with knowledge about what real peptide science looks like versus marketing fabrication